Triveni Bio has dosed the first healthy volunteers in its Phase I study of TRIV-573, a half-life extended bispecific antibody aimed at kallikreins 5 and 7 (KLK5/7) and interleukin 13 (IL-13).
With the ongoing changes in atopic dermatitis (AD) treatment, TRIV-573’s dual-targeting of KLK5/7 and IL-13 aims to address both skin barrier dysfunction and inflammation.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial investigates a combination approach that uses KLK5/7 inhibition for barrier repair alongside IL-13 blockade for anti-inflammatory effect, which seeks to meet unmet needs in moderate-to-severe AD.
Triveni Bio chief medical officer Bhaskar Srivastava said: “TRIV-573 builds on compelling preclinical evidence that KLK5/7 inhibition addresses all three pillars of AD pathology: barrier, inflammation, and itch.
“We have demonstrated preclinical additivity when combining the KLK5/7 mechanism with Th2 targeting, positioning TRIV-573 as a novel combination approach for moderate-to-severe AD with a single therapeutic designed for infrequent, patient-friendly dosing.”
The Phase I trial launch extends Triveni Bio’s clinical pipeline, with plans to advance towards a Phase II proof-of-concept study in the second half of 2026.
The company develops genetics-informed antibody therapies for immunological and inflammatory (I&I) disorders.
Triveni Bio CEO Vishal Patel said: “Advancing TRIV-573 into the clinic less than one year after TRIV-509 is a testament to our team’s execution.
“We are thrilled to progress this unique therapy as we work to break the existing efficacy ceiling for patients with AD and other I&I disorders.”
Triveni Bio’s lead programme, TRIV-509 (anti-KLK5/7), is being studied in an ongoing Phase II trial for moderate-to-severe AD, with results expected at the end of 2026.
